Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 23.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2NB17 ISIN: US0547547002 Ticker-Symbol: AY21 
Frankfurt
23.10.19
16:11 Uhr
1,010 Euro
+0,015
+1,51 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AYTU BIOSCIENCE INC Chart 1 Jahr
5-Tage-Chart
AYTU BIOSCIENCE INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,020
1,040
22:00

Aktuelle News zur AYTU BIOSCIENCE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAytu Bio's Tuzistra XR now added to PBM's formulary-
Börsennews zur AYTU BIOSCIENCE Aktie und weiteren Hot Stocks erhalten
MoAytu BioScience, Inc.: Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary130Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives U.S. Cough Cold Prescription Market is Worth in Excess of $3 Billion at Current Brand Pricing, with 30-35 Million Prescriptions...
► Artikel lesen
DoAytu BioScience, Inc.: Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study247Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T Natesto Increased Serum Testosterone...
► Artikel lesen
16.10.Aytu Bio up 11% premarket ahead of Natesto data-
16.10.Aytu BioScience, Inc.: Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17194Investigator-initiated, Phase IV study results will be presented today at 75th Annual American Society for Reproductive Medicine (ASRM) scientific conference "Late Breaking' abstract session ENGLEWOOD...
► Artikel lesen
15.10.AYTU BIOSCIENCE, INC - 8-K, Current Report-
15.10.Aytu BioScience, Inc. (AYTU) CEO Josh Disbrow on Commercial Portfolio Acquisition Overview Conference - Slide Presentation-
15.10.Aytu BioScience, Inc. (AYTU) CEO Josh Disbrow on Commercial Portfolio Acquisition Overview Conference (Transcript)-
14.10.Aytu Bio acquires prescription product portfolio for $17M-
14.10.Aytu Bio launches $10M private placement-
14.10.Cerecor Inc.: Cerecor To Sell Pediatric Portfolio to AYTU BioScience-
14.10.Aytu BioScience, Inc.: Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio365Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acquisition of Innovus Pharmaceuticals Total upfront consideration equals...
► Artikel lesen
14.10.Aytu BioScience, Inc.: Aytu BioScience Announces $10 Million Private Placement282Armistice Capital and Altium Capital jointly participated in financing ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused...
► Artikel lesen
02.10.Aytu BioScience, Inc.: Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market223Co-Promotion Expands Physician Promotion of Aytu's Prescription Sleep Aid with Dedicated Specialty Sales Force, into Psychiatry Market, Which Accounted for Over 2.7 Million Zolpidem Tartrate Prescriptions...
► Artikel lesen
27.09.Aytu BioScience, Inc. (AYTU) CEO Josh Disbrow on Q4 2019 Results - Earnings Call Transcript-
26.09.AYTU BIOSCIENCE, INC - 10-K, Annual Report-
26.09.Aytu BioScience EPS misses by $1.33, misses on revenue-
26.09.Aytu BioScience, Inc.: Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019288Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies product line by 10x to over 30 products ENGLEWOOD, CO...
► Artikel lesen
26.09.AYTU BIOSCIENCE, INC - 8-K, Current Report-
24.09.Aytu BioScience (AYTU) Presents at Ladenburg Thalmann 2019 Healthcare Conference - Slide Presentation-
Seite:  Weiter >>
75 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1